Patients who develop hypercalcemia on CCPB tend to have low bone density, suggesting reduced capacity for bone to buffer calcium loads.
Vascular calcification has been shown to occur only when patients are in positive calcium balance.
Randomized control trials have shown that sevelamer hydrochloride is less likely to be associated with cardiovascular mortality than comparable phosphate control with CCPB.
Extensive vascular calcification had been rarely seen before the advent of the use of CCPB.
Calcimimetics effectively reduce intact parathyroid hormone (PTH) levels only when the value is less than 400 pg/ml.
Calcimimetics tend to raise the serum PO4 levels in hemodialysis patients.
Ca PO4 product tends to slightly increase in patients receiving calcimimetics.
Calcimimetics reduce intact PTH levels while concurrently reducing Ca PO4 product.
Calciphylaxis associated with adynamic bone disease.
Calciphylaxis with intermittent hyperphosphatemia.
Calciphylaxis secondary to intermittent hyperparathyroidism.
The first-generation intact PTH assay measures both 1-84 and 7-84 moieties of PTH.
The ratio of 1-84/7-84 more accurately predicts the histologic state of bone than the intact PTH assay.
A low 7-84 moiety in the face of a low 1-84 moiety rules out low turnover bone disease.
A low intact PTH in the face of a high 7-84 moiety indicates the presence of adynamic bone disease.
Every 14 months
1.00 and 1.25 mmol/l
1.25 and 1.50 mmol/l
1.50 and 1.75 mmol/l
None of the above